Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly raltitrexed plus oxaliplatin or irinotecan in previously treated advanced colorectal cancer
ChiCTR-ONRC-13004046Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of raltitrexed, oxaliplatin and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: response rate. Started Nov 2013; status: completed.
02
Drugs
raltitrexedoxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-ONRC-13004046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-13004046.